Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 444,889
  • Shares Outstanding, K 49,159
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -97,090 K
  • 60-Month Beta 0.44
  • Price/Sales 101.33
  • Price/Cash Flow N/A
  • Price/Book 2.17
Trade ALT with:

Options Overview Details

View History
  • Implied Volatility 131.14% ( -3.59%)
  • Historical Volatility 80.88%
  • IV Percentile 78%
  • IV Rank 54.66%
  • IV High 210.69% on 09/13/22
  • IV Low 35.26% on 03/16/22
  • Put/Call Vol Ratio 0.04
  • Today's Volume 28
  • Volume Avg (30-Day) 790
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 40,776
  • Open Int (30-Day) 39,099

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.48
  • Low Estimate -0.57
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -4.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.29 +11.82%
on 11/22/22
13.29 -30.25%
on 11/01/22
-3.50 (-27.41%)
since 10/28/22
3-Month
8.29 +11.82%
on 11/22/22
23.49 -60.54%
on 09/02/22
-10.13 (-52.22%)
since 08/29/22
52-Week
3.83 +142.04%
on 05/12/22
23.49 -60.54%
on 09/02/22
-1.15 (-11.04%)
since 11/26/21

Most Recent Stories

More News
My 3 Top Biotech Stock Picks for 2023

Biotech stocks are set to shine in 2023.

XBI : 80.48 (+1.04%)
ALT : 9.28 (+2.54%)
KRTX : 225.88 (+1.01%)
VKTX : 4.01 (unch)
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALT : 9.28 (+2.54%)
INFI : 0.5400 (+0.47%)
Alternus Energy Group plc Announces Altnua, a Dedicated Clean Energy Development Business to Drive Organic Growth into the Future

Alternus Energy Group plc ("Alternus") (OSE: ALT) today announced the establishment of its development business, Altnua, which aims to become one of the leading specialist renewable asset developers in...

ALT : 9.28 (+2.54%)
CLIN : 9.99 (+0.10%)
Alternus Energy Group Plc Announces Business Combination Agreement with Clean Earth Acquisitions Corp.

Alternus Energy Group Plc (" Alternus " or the " Company ") (OSE: ALT) and Clean Earth Acquisitions Corp. (NASDAQ: CLIN) (“ Clean Earth ”), a climate technology and energy transition-focused special...

ALT : 9.28 (+2.54%)
CLIN : 9.99 (+0.10%)
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

ALT : 9.28 (+2.54%)
ICPT : 14.48 (-0.55%)
ACER : 1.1401 (-2.42%)
AKRO : 44.74 (-1.54%)
ALTIMMUNE INC (ALT) Q2 2022 Earnings Call Transcript

ALT earnings call for the period ending June 30, 2022.

ALT : 9.28 (+2.54%)
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ALT : 9.28 (+2.54%)
FTRP : 4.2105 (+1.07%)
Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy

Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

ALT : 9.28 (+2.54%)
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?

Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.

ALT : 9.28 (+2.54%)
ARGX : 375.55 (-0.91%)
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M

Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.

MOH : 329.01 (+0.76%)
CI : 320.62 (+0.35%)
ALT : 9.28 (+2.54%)
PGNY : 36.64 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.88
2nd Resistance Point 9.68
1st Resistance Point 9.36
Last Price 9.28
1st Support Level 8.84
2nd Support Level 8.64
3rd Support Level 8.33

See More

52-Week High 23.49
Fibonacci 61.8% 15.98
Fibonacci 50% 13.66
Fibonacci 38.2% 11.34
Last Price 9.28
52-Week Low 3.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar